Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 57 Carcinoma, Non-Small-Cell Lung 34 Urinary Bladder Neoplasms 29 Neoplasm Metastasis 20 Lung Neoplasms 19 Ovarian Neoplasms 18 Lymphoma, Large B-Cell, Diffuse 18 Cholangiocarcinoma 15 Biliary Tract Neoplasms 14 Triple Negative Breast Neoplasms 13 Neoplasms 13 Nasopharyngeal Carcinoma 13 Colorectal Neoplasms 12 Breast Neoplasms 12 Carcinoma, Transitional Cell 11 Non-Muscle Invasive Bladder Neoplasms 10 Recurrence 9 Fallopian Tube Neoplasms 9 Gallbladder Neoplasms 8 Sarcoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Bile Duct Neoplasms 6 Osteosarcoma 5 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Endometrial Neoplasms 5 Uterine Cervical Neoplasms 4 Melanoma 4 Hodgkin Disease 4 Colonic Neoplasms 4

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Gemcitabine × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡